Do the benefits outweigh the risks with drug-eluting stents?
Kløw
Nils Einar
NE
D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control*; D000068338:Everolimus; D006801:Humans; D017239:Paclitaxel / Q000009:adverse effects*; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011474:Prosthesis Design; D018570:Risk Assessment; D020123:Sirolimus / Q000009:adverse effects* / Q000031:analogs & derivatives; D015607:Stents / Q000009:adverse effects*; D013927:Thrombosis / Q000139:chemically induced* / Q000517:prevention & control
D010975:Platelet Aggregation Inhibitors; D000068338:Everolimus; C489443:zotarolimus; D017239:Paclitaxel; D020123:Sirolimus